What are the latest news and developments about Ocriplasmin in China?

Ocriplasmin (Ocriplasmin) is a recombinant protein drug that was approved for marketing by the US FDA in October 2012 under the trade name Jetrea. It is mainly used to treat ophthalmic diseases related to vitreous adhesion, such as vitreomacular traction syndrome. Its mechanism of action is to help patients relieve traction by breaking down the protein adhesion between the vitreous body and the retina, thereby improving the macular structure and visual function. As an innovative ophthalmic drug, Oakplasmin has attracted the attention of ophthalmologists after being launched in Europe, the United States and other countries, and is considered a new non-surgical option in the field of macular disease treatment.

However, as far as the Chinese market is concerned, there is currently no news of the official launch of Oak Plasmin. This means that the drug is temporarily not included in the domestic drug registration catalog and cannot be used through medical insurance reimbursement channels. Domestic ophthalmology clinics still mainly rely on traditional treatment methods such as vitrectomy surgery. For patients who are not suitable for surgery or who hope to solve the vitreous traction through drugs, the absence of Oak plasmin is a pity.

In recent years, China has significantly accelerated the introduction of rare diseases and innovative drugs, and a number of international new ophthalmic drugs have successively entered the Chinese market and conducted localized clinical trials. Therefore, there is still potential for the introduction of Oak plasmin in China in the future, especially in the context of the gradual increase in the prevalence of retinal diseases and the intensification of population aging, and the clinical demand for innovative ophthalmic drugs is growing.

At the policy level, China has set up a green channel for the review and approval of innovative drugs, especially the accelerated introduction of drugs related to fundus diseases, such as antiVEGF drugs, which provide a positive signal for the future entry of Oak plasmin into the country. If the drug can conduct registered clinical trials in the future and be approved for marketing, it will provide new treatment options for patients with vitreomacular traction syndrome and reduce surgical risks.

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html